These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 38453818)

  • 1. Immune landscape and response to oncolytic virus-based immunotherapy.
    Lin C; Teng W; Tian Y; Li S; Xia N; Huang C
    Front Med; 2024 Jun; 18(3):411-429. PubMed ID: 38453818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
    Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.
    Kim Y; Clements DR; Sterea AM; Jang HW; Gujar SA; Lee PW
    Viruses; 2015 Dec; 7(12):6506-25. PubMed ID: 26690204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
    Yun CO; Hong J; Yoon AR
    Front Immunol; 2022; 13():953410. PubMed ID: 36091031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
    Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
    Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.
    Wang L; Chard Dunmall LS; Cheng Z; Wang Y
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
    Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
    Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells.
    Leung EYL; McNeish IA
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells.
    Soroush A; Shahhosseini R; Ghavamikia N; Hjazi A; Roudaki S; KhalatbariLimaki M; Mirbolouk M; Pakmehr S; Karimi P
    Cell Biochem Funct; 2024 Jun; 42(4):e4055. PubMed ID: 38856033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.
    Stergiopoulos GM; Concilio SC; Galanis E
    Curr Treat Options Oncol; 2024 Jul; 25(7):952-991. PubMed ID: 38896326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.